van Dalen EC - Search Results

1

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.

Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR; CPNDS Consortium. Visscher H, et al. Among authors: van der pal hj, van dalen ec. Pediatr Blood Cancer. 2013 Aug;60(8):1375-81. doi: 10.1002/pbc.24505. Epub 2013 Feb 25. Pediatr Blood Cancer. 2013. PMID: 23441093 Clinical Trial.

2

A call for harmonized surveillance recommendations in cardio-oncology.

Leerink JM, Ehrhardt MJ, van Dalen EC. Leerink JM, et al. Among authors: van dalen ec. Eur Heart J. 2023 Aug 14;44(31):3017-3018. doi: 10.1093/eurheartj/ehad268. Eur Heart J. 2023. PMID: 37350756 No abstract available.

3

Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.

Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voûte PA. Kremer LC, et al. Among authors: van dalen ec. J Clin Oncol. 2001 Jan 1;19(1):191-6. doi: 10.1200/JCO.2001.19.1.191. J Clin Oncol. 2001. PMID: 11134212

4

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.

Kremer LC, van Dalen EC, Offringa M, Voûte PA. Kremer LC, et al. Among authors: van dalen ec. Ann Oncol. 2002 Apr;13(4):503-12. doi: 10.1093/annonc/mdf118. Ann Oncol. 2002. PMID: 12056699 Free article. Review.

5

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voûte PA. Kremer LC, et al. Among authors: van der pal hj, van dalen ec. Ann Oncol. 2002 Jun;13(6):819-29. doi: 10.1093/annonc/mdf167. Ann Oncol. 2002. PMID: 12123328 Free article. Review.

6

Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence.

van Dalen EC, van der Pal HJ, van den Bos C, Caron HN, Kremer LC. van Dalen EC, et al. Among authors: van den bos c, van der pal hj. J Clin Oncol. 2003 Sep 1;21(17):3377; author reply 3377-8. doi: 10.1200/JCO.2003.99.006. J Clin Oncol. 2003. PMID: 12947081 No abstract available.

7

Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review.

van Dalen EC, van der Pal HJ, Bakker PJ, Caron HN, Kremer LC. van Dalen EC, et al. Among authors: van der pal hj. Eur J Cancer. 2004 Mar;40(5):643-52. doi: 10.1016/j.ejca.2003.12.006. Eur J Cancer. 2004. PMID: 15010064 Review.

8

Cardioprotective interventions for cancer patients receiving anthracyclines.

van Dalen EC, Caron HN, Dickinson HO, Kremer LC. van Dalen EC, et al. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003917. doi: 10.1002/14651858.CD003917.pub2. Cochrane Database Syst Rev. 2005. PMID: 15674919 Updated. Review.

9

Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review.

van der Pal HJ, van Dalen EC, Kremer LC, Bakker PJ, van Leeuwen FE. van der Pal HJ, et al. Among authors: van dalen ec, van leeuwen fe. Cancer Treat Rev. 2005 May;31(3):173-85. doi: 10.1016/j.ctrv.2005.03.008. Cancer Treat Rev. 2005. PMID: 15896910 Review.

10

Management of asymptomatic anthracycline-induced cardiac damage after treatment for childhood cancer: a postal survey among Dutch adult and pediatric cardiologists.

van Dalen EC, van der Pal HJ, Reitsma JB, de Winter RJ, Helbing WA, Ottenkamp J, Caron HN, Kremer LC. van Dalen EC, et al. Among authors: van der pal hj. J Pediatr Hematol Oncol. 2005 Jun;27(6):319-22. doi: 10.1097/01.mph.0000170887.27958.27. J Pediatr Hematol Oncol. 2005. PMID: 15956885

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

133 results

Search Page